What are the side effects of Myrbetriq (Mirabegron)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Mybetriq (mirabegron) can cause several side effects, including hypertension, UTIs, headache, and nasopharyngitis, as reported in a 2023 meta-analysis of eight randomised controlled trials 1. When considering the management of non-neurogenic male lower urinary tract symptoms (MLUTS) with Mybetriq, it is essential to weigh the benefits against the potential risks. The most frequent adverse events (AEs) associated with mirabegron include:

  • Hypertension
  • Urinary tract infections (UTIs)
  • Headache
  • Nasopharyngitis These side effects are well-documented in the literature, with a recent study published in the European Urology journal highlighting the safety profile of mirabegron 1. It is crucial to note that mirabegron is contraindicated in patients with severe uncontrolled hypertension, and its use should be carefully considered in patients with multiple comorbidities 1. Regular blood pressure monitoring is recommended, especially when starting this medication, to minimize the risk of adverse events. Patients should be aware of the potential side effects and discuss any concerns with their healthcare provider before starting treatment with Mybetriq.

From the FDA Drug Label

The most commonly reported adverse reactions (greater than 2% of mirabegron patients and greater than placebo) were hypertension, nasopharyngitis, urinary tract infection, and headache The most common side effects of mirabegron extended-release tablets include: • high blood pressure • pain or swelling of the nose or throat (nasopharyngitis) • urinary tract infection • headache Mirabegron extended-release tablets may cause serious side effects, including: • increased blood pressure. • inability to empty your bladder (urinary retention) • angioedema

Common side effects of Mybetriq (mirabegron) include:

  • Hypertension
  • Nasopharyngitis
  • Urinary tract infection
  • Headache Serious side effects of Mybetriq (mirabegron) include:
  • Increased blood pressure
  • Urinary retention
  • Angioedema 2 2

From the Research

Mybetriq Side Effects

Mybetriq, also known as mirabegron, is a medication used to treat overactive bladder (OAB) symptoms. The common side effects of mirabegron include:

  • Hypertension
  • Nasopharyngitis
  • Urinary tract infection
  • Headache
  • Constipation
  • Upper respiratory tract infection
  • Arthralgia
  • Diarrhea
  • Tachycardia
  • Abdominal pain
  • Fatigue 3, 4, 5, 6

Comparison with Other Treatments

Mirabegron has been compared to other treatments for OAB, such as tolterodine, in terms of efficacy and safety. Studies have shown that mirabegron is effective in reducing incontinence episodes, micturitions, and urgency episodes, and improving voided volume 3, 4, 6. Additionally, mirabegron has been found to have a good safety profile, with a lower risk of overall treatment-emergent adverse events compared to tolterodine 6.

Specific Side Effects

Some studies have reported specific side effects associated with mirabegron, including:

  • Dry mouth, which is less common compared to antimuscarinic agents 3
  • Hypertension, which is a common side effect 3, 4, 5, 6
  • Cardiac arrhythmia, which has been reported in some studies 6
  • Urinary tract infection, which is a common side effect 3, 4, 5, 6

Long-Term Safety

The long-term safety of mirabegron has been evaluated in several studies, which have shown that it is well-tolerated and effective in reducing OAB symptoms over a period of 12 months 3, 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Mirabegron: a Beta-3 agonist for overactive bladder.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2014

Research

Mirabegron in the Management of Overactive Bladder Syndrome.

International journal of women's health, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.